Spectral Diagnostics Raises $14 Million, to Collaborate With BioMS

Spectral Diagnostics Inc. and BioMS Medical Corp. announced that BioMS Medical and a syndicate of investors have invested $14 million in Spectral Diagnostics to advance Toraymyxin, a treatment for severe sepsis, towards regulatory approval and commercialization in the United States.
Forbes